8-K: Sight Sciences Announces Q3 2024 Results, Leadership Changes, and Updated Guidance

Sight Sciences reported a slight revenue increase for Q3 2024, appointed a new COO, and updated its full-year adjusted operating expense guidance.

Summary

• Sight Sciences reported a 1% increase in total revenue for the third quarter of 2024, reaching $20.2 million.
• Surgical Glaucoma revenue also saw a 1% increase, driven by higher account utilization, while Dry Eye revenue decreased by 4%.
• The company achieved positive cash flow of $0.4 million in Q3 2024, a significant improvement from the $10.0 million cash used in the same period last year.
• Gross profit was $16.9 million, with a gross margin of 84%, down from 87% in the prior year due to higher overhead costs.
• Operating expenses decreased by 8% to $28.1 million, primarily due to lower legal expenses.
• Adjusted operating expenses decreased by 11% to $23.8 million.
• Net loss was $11.1 million, or $0.22 per share, compared to a $13.0 million loss, or $0.27 per share, in the same quarter of the previous year.
• The company maintains its full-year 2024 revenue guidance of approximately $81.0 million to $83.0 million.
• Adjusted operating expense guidance for the full year 2024 has been revised to approximately $104.0 million to $106.0 million.
• The company expects double-digit Surgical Glaucoma revenue growth in the fourth quarter of 2024.
• Dry Eye revenue is expected to be less than $0.5 million in the fourth quarter of 2024 due to a price increase.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like improved cash flow and reduced operating expenses, the slower than expected revenue growth in Surgical Glaucoma, the decrease in Dry Eye revenue, and the expected negative impact of the price increase on Dry Eye revenue in Q4 temper the overall outlook.

Positives

• The company achieved positive cash flow in Q3 2024, a significant turnaround from the previous year.
• Operating expenses and adjusted operating expenses decreased, indicating improved cost management.
• The company maintains its full-year revenue guidance.
• Medicare coverage for cataract surgery with a single MIGS procedure was confirmed by five MACs.
• The company expects double-digit Surgical Glaucoma revenue growth in the fourth quarter of 2024.
• The company has appointed a new Executive Vice President of Operations with extensive experience in medical technology.

Negatives

• Surgical Glaucoma revenue growth was slower than expected.
• Dry Eye revenue decreased by 4% in Q3 2024.
• Gross margin decreased from 87% to 84% due to higher overhead costs.
• Dry Eye revenue is expected to be less than $0.5 million in the fourth quarter of 2024 due to a price increase.
• The company acknowledges headwinds to growth in the total number of MIGS devices used in MIGS procedures due to the Final LCDs limitations on multiple MIGS used in a single surgery.

Risks

• Changes to coverage decisions or reimbursement rates for the company's products could impact revenue.
• Pricing pressure or loss of market share due to competition could affect the company's performance.
• Disruptions to or increased costs associated with the supply chain could negatively impact the company.
• The company faces headwinds to growth in the total number of MIGS devices used in MIGS procedures due to the Final LCDs limitations on multiple MIGS used in a single surgery.
• The price increase for Dry Eye treatments is expected to have a significant negative impact on cash-pay procedure volumes in the fourth quarter of 2024.

Future Outlook

The company expects double-digit Surgical Glaucoma revenue growth in the fourth quarter of 2024 and anticipates a return to growth in Dry Eye revenue in 2025 after addressing market access issues. The company has revised its adjusted operating expense guidance for the full year 2024 to approximately $104.0 million to $106.0 million.

Management Comments

• Paul Badawi, CEO, stated that while Surgical Glaucoma revenue improved slightly, it did not meet growth expectations, but Dry Eye revenue outperformed expectations.
• Paul Badawi also mentioned that the LCDs will provide clarity with continued Medicare coverage for cataract surgery procedures performed with a single MIGS procedure.
• Paul Badawi expressed confidence in the growth trajectory for OMNI in both combination cataract and standalone use cases in 2025 and beyond.
• Paul Badawi stated that the company is focused on establishing equitable market access for TearCare and is working towards positive coverage policies and payment schedules in 2025.
• MK Raheja, Executive Vice President, Research and Development, stated that he is delighted to be joining Sight Sciences at this critical juncture with major projects in development.
• Brenton Taylor, Executive Vice President, Operations, stated that he looks forward to working with the team to improve the lives of patients and help the company scale in a capital efficient way.

Industry Context

The announcement comes as the medical device industry continues to focus on minimally invasive procedures and innovative solutions for eye care. The confirmation of Medicare coverage for MIGS procedures is a positive development for the glaucoma market, while the company's focus on market access for its dry eye treatment aligns with the growing demand for effective solutions in this area.

Comparison to Industry Standards

• Sight Sciences' revenue growth of 1% in Surgical Glaucoma is below the growth rates of some competitors in the MIGS market, such as Glaukos, which has reported higher growth rates in recent quarters.
• The company's gross margin of 84% is within the range of other medical device companies, but the decrease from 87% indicates potential challenges in cost management.
• The positive cash flow of $0.4 million is a significant improvement, but the company still needs to demonstrate consistent profitability to be competitive with established players in the industry.
• The company's focus on standalone MIGS procedures aligns with the industry trend of expanding the use of MIGS beyond combination cataract surgeries, but it needs to demonstrate strong clinical outcomes to gain market share.
• The company's TearCare system competes with other dry eye treatments, such as Allergan's Restasis, and the SAHARA trial results are important for establishing its competitive position.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the slower than expected revenue growth and the decrease in gross margin.
• Employees may be affected by the leadership changes and the company's focus on cost management.
• Customers may benefit from the company's continued innovation and focus on improving treatment options.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.
• Creditors may be reassured by the company's improved cash flow and reduced operating expenses.

Next Steps

• The company will focus on regaining commercial momentum and expanding utilization and its customer base in Surgical Glaucoma.
• The company will work towards establishing equitable market access for TearCare and positive coverage policies and payment schedules in 2025.
• The company will continue to develop its product pipeline in surgical glaucoma and dry eye.
• The company will continue to optimize its commercial organization and strategy.

Key Dates

Keywords

Sight Sciences, Glaucoma, Dry Eye, MIGS, OMNI Surgical System, TearCare, Financial Results, Operating Expenses, Medicare Coverage, Executive Appointment